



Leucine-Rich Repeat Serine/threonine-Protein Kinase 2 (PARK8) Antibody

Catalogue No.: abx033176



Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson's disease identified to date. LRRK2, a genetic mutation, was recently found linked to about 5 percent of inherited cases of Parkinson's disease. By high-resolution recombination mapping and candidate gene sequencing in 46 families, 6 disease-segregating mutations (5 missense and 1 putative splice site mutation). It may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism. LRRK2 belongs to the Roco protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.

Target: Leucine-Rich Repeat Serine/threonine-Protein Kinase 2 (PARK8)

Clonality: Polyclonal

Reactivity: Human

Tested Applications: ELISA, WB, IHC

Datasheet

Version: 2.0.0
Revision date: 03 Jul 2025



Host: Rabbit

Recommended dilutions: WB: 1/1000, IHC-P: 1/50 - 1/100. Not tested in IHC-F. Optimal dilutions/concentrations should be determined by the end user.

Conjugation: Unconjugated

Immunogen: KLH-conjugated synthetic peptide between 931-962 amino acids from human PARK8 (LRRK2).

Isotype: IgG

Form: Liquid

Purification: Purified Rabbit Polyclonal Antibody.

Storage: Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

UniProt Primary AC: Q5S007 ([UniProt](#), [ExPASy](#))

NCBI Accession: NP_940980.3

KEGG: hsa:120892

String: [9606.ENSP00000298910](#)

Molecular Weight: Calculated MW: 286 kDa

Buffer: PBS containing 0.09% sodium azide.

Note: THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.